



Crescendo Biologics' Colette Johnston to Present at 11th Annual Proteins & Antibodies Congress 17 April 2018

Cambridge, UK, 15 March 2018 – Crescendo Biologics Limited (Crescendo), the drug developer of novel, targeted T-cell engaging therapeutics, announces that Colette Johnston, Senior Director, will be presenting at the 11th Annual Proteins & Antibodies Congress in London, UK on 17 April 2018.

The 11th Annual Proteins & Antibodies Congress is being held in London from 16–17 April and brings together over 450 attendees, ranging from global pharmaceutical organisations and leading biotech companies to internationally renowned academic institutions.

Colette will present a talk on “*Developing Differentiated Humabody[®] V_H Therapeutics for Oncology*” within the ‘Antibody Engineering, Design & Development’ and ‘Protein & Antibody Biotherapeutics’ streams. Several other scientists from Crescendo will also be in attendance.

Title: Developing Differentiated Humabody[®] V_H Therapeutics for Oncology

Date: Tuesday 17 April 2018

Time: 17.00

Location: Novotel London West Hotel, 1 Shortlands, Hammersmith International Centre, London, UK W6 8DR

Ends

For more information, please contact:

Crescendo Biologics Dr Peter Pack, CEO	Tel: 44 (0)1223 497140 info@crescendobiologics.com
Instinctif Partners Deborah Bell / Dr Christelle Kerouedan	Tel: 44 (0)20 7457 2020 crescendo@instinctif.com



Notes to Editors:

About Crescendo Biologics Ltd

Crescendo Biologics is a biopharmaceutical company developing potent, highly differentiated multi-functional Humabody[®] therapeutics in oncology, with an internal focus on biologics for Targeted T-cell Therapy with novel modes-of-action. It is pursuing novel Humabody[®]-based product opportunities, through in-house development and strategic partnerships, in both multi- functional immuno-oncology modulators and Humabody[®] Drug Conjugates (HDCs), the next generation of ADCs.

The Company's Humabody[®] therapeutics are based on its unique, patent protected, transgenic mouse platform, generating 100% human V_H domain building blocks (Humabody[®] V_H) comprising the full structural diversity of the human V_H repertoire and superior biophysical properties as a result of their in vivo maturation.

Crescendo is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Touchstone Innovations (formerly known as Imperial Innovations), Takeda and Astellas.

For more information, please visit the website: www.crescendobiologics.com